Puma Biotechnology, Inc.
PBYI
$5.06
$0.193.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.96% | 8.63% | 2.68% | -2.19% | 6.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.96% | 8.63% | 2.68% | -2.19% | 6.30% |
| Cost of Revenue | -34.56% | 11.67% | 6.71% | 2.75% | 35.53% |
| Gross Profit | -3.39% | 7.52% | 1.23% | -3.98% | -2.98% |
| SG&A Expenses | -16.86% | -22.44% | -14.17% | -10.24% | -14.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.25% | -3.81% | -2.28% | -1.42% | 3.58% |
| Operating Income | 1.62% | 135.86% | 40.03% | -6.91% | 27.71% |
| Income Before Tax | 25.33% | 319.97% | 93.35% | 6.29% | 441.16% |
| Income Tax Expenses | -525.61% | -558.28% | -628.11% | -670.45% | 69.44% |
| Earnings from Continuing Operations | 59.11% | 455.63% | 147.59% | 40.23% | 525.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.11% | 455.63% | 147.59% | 40.23% | 525.26% |
| EBIT | 1.62% | 135.86% | 40.03% | -6.91% | 27.71% |
| EBITDA | 0.19% | 84.38% | 27.62% | -5.12% | 20.72% |
| EPS Basic | 56.02% | 429.89% | 137.93% | 34.91% | 537.28% |
| Normalized Basic EPS | 19.49% | 278.38% | 79.21% | -0.52% | 63.31% |
| EPS Diluted | 59.60% | 462.82% | 145.34% | 37.38% | 569.02% |
| Normalized Diluted EPS | 19.36% | 281.99% | 80.15% | -0.30% | 62.87% |
| Average Basic Shares Outstanding | 2.92% | 3.03% | 3.12% | 3.22% | 3.41% |
| Average Diluted Shares Outstanding | 3.46% | 3.27% | 2.89% | 2.55% | 3.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |